FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038118150> ?p ?o ?g. }

• W2038118150 endingPage "1331" @default.
• W2038118150 startingPage "1322" @default.
• W2038118150 abstract "Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7.BackgroundThe secondary hyperparathyroidism of chronic kidney disease (CKD) produces a high turnover osteodystrophy that is associated with peritrabecular fibrosis. The nature of the cells involved in the development of peritrabecular fibrosis may represent osteoprogenitors expressing a fibroblastic phenotype that are retarded from progressing through osteoblast differentiation.MethodsTo test the hypothesis that osteoblast differentiation is retarded in secondary hyperparathyroidism due to CKD producing bone marrow fibrosis, we administered bone morphogenetic protein 7 (BMP-7), a physiologic regulator of osteoblast regulation, to C57BL6 mice that had CKD produced by electrocautery of one kidney followed by contralateral nephrectomy two weeks later. Following the second surgical procedure, a subgroup of mice received daily intraperitoneal injections of BMP-7 (10 μg/kg). Three to six weeks later, the animals were sacrificed, blood was obtained for measurements of blood urea nitrogen (BUN) and parathyroid hormone (PTH) levels, and the femora and tibiae were processed for histomorphometric analysis.ResultsThe animals had significant renal insufficiency with BUN values of 77.79 ± 22.68 mg/dL, and the level of renal impairment between the CKD untreated mice and the CKD mice treated with BMP-7 was the same in the two groups. PTH levels averaged 81.13 ± 51.36 and 75.4 ± 43.61 pg/mL in the CKD and BMP-7 treated groups, respectively. The animals with CKD developed significant peritrabecular fibrosis. In addition, there was an increase in osteoblast surface and osteoid accumulation as well as increased activation frequency and increased osteoclast surface consistent with high turnover renal osteodystrophy. Treatment with BMP-7 eliminated peritrabecular fibrosis, increased osteoblast number, osteoblast surface, mineralizing surface and single labeled surface. There was also a significant decrease in the eroded surface induced by treatment with BMP-7.ConclusionsThese findings indicate that BMP-7 treatment in the setting of high turnover renal osteodystrophy prevents the development of peritrabecular fibrosis, affects the osteoblast phenotype and mineralizing surfaces, and decreases bone resorption. This is compatible with a role of osteoblast differentiation in the pathophysiology of osteitis fibrosa. Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7. The secondary hyperparathyroidism of chronic kidney disease (CKD) produces a high turnover osteodystrophy that is associated with peritrabecular fibrosis. The nature of the cells involved in the development of peritrabecular fibrosis may represent osteoprogenitors expressing a fibroblastic phenotype that are retarded from progressing through osteoblast differentiation. To test the hypothesis that osteoblast differentiation is retarded in secondary hyperparathyroidism due to CKD producing bone marrow fibrosis, we administered bone morphogenetic protein 7 (BMP-7), a physiologic regulator of osteoblast regulation, to C57BL6 mice that had CKD produced by electrocautery of one kidney followed by contralateral nephrectomy two weeks later. Following the second surgical procedure, a subgroup of mice received daily intraperitoneal injections of BMP-7 (10 μg/kg). Three to six weeks later, the animals were sacrificed, blood was obtained for measurements of blood urea nitrogen (BUN) and parathyroid hormone (PTH) levels, and the femora and tibiae were processed for histomorphometric analysis. The animals had significant renal insufficiency with BUN values of 77.79 ± 22.68 mg/dL, and the level of renal impairment between the CKD untreated mice and the CKD mice treated with BMP-7 was the same in the two groups. PTH levels averaged 81.13 ± 51.36 and 75.4 ± 43.61 pg/mL in the CKD and BMP-7 treated groups, respectively. The animals with CKD developed significant peritrabecular fibrosis. In addition, there was an increase in osteoblast surface and osteoid accumulation as well as increased activation frequency and increased osteoclast surface consistent with high turnover renal osteodystrophy. Treatment with BMP-7 eliminated peritrabecular fibrosis, increased osteoblast number, osteoblast surface, mineralizing surface and single labeled surface. There was also a significant decrease in the eroded surface induced by treatment with BMP-7. These findings indicate that BMP-7 treatment in the setting of high turnover renal osteodystrophy prevents the development of peritrabecular fibrosis, affects the osteoblast phenotype and mineralizing surfaces, and decreases bone resorption. This is compatible with a role of osteoblast differentiation in the pathophysiology of osteitis fibrosa." @default.
• W2038118150 created "2016-06-24" @default.
• W2038118150 creator A5011328038 @default.
• W2038118150 creator A5042111434 @default.
• W2038118150 creator A5042816552 @default.
• W2038118150 creator A5042945151 @default.
• W2038118150 creator A5049273344 @default.
• W2038118150 creator A5055986991 @default.
• W2038118150 creator A5084433382 @default.
• W2038118150 date "2002-04-01" @default.
• W2038118150 modified "2023-09-27" @default.
• W2038118150 title "Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7" @default.
• W2038118150 cites W1507752960 @default.
• W2038118150 cites W1551461802 @default.
• W2038118150 cites W1967092942 @default.
• W2038118150 cites W1968814931 @default.
• W2038118150 cites W1968822620 @default.
• W2038118150 cites W1971077979 @default.
• W2038118150 cites W1979643551 @default.
• W2038118150 cites W1980473444 @default.
• W2038118150 cites W1981089517 @default.
• W2038118150 cites W1982789076 @default.
• W2038118150 cites W1985753282 @default.
• W2038118150 cites W1986526390 @default.
• W2038118150 cites W1999033913 @default.
• W2038118150 cites W2001480762 @default.
• W2038118150 cites W2010299883 @default.
• W2038118150 cites W2010789237 @default.
• W2038118150 cites W2052127095 @default.
• W2038118150 cites W2062207135 @default.
• W2038118150 cites W2078496129 @default.
• W2038118150 cites W2081070288 @default.
• W2038118150 cites W2087378917 @default.
• W2038118150 cites W2088255854 @default.
• W2038118150 cites W2091978538 @default.
• W2038118150 cites W2094516179 @default.
• W2038118150 cites W2101148973 @default.
• W2038118150 cites W2106920682 @default.
• W2038118150 cites W2114245705 @default.
• W2038118150 cites W2117858504 @default.
• W2038118150 cites W2123586641 @default.
• W2038118150 cites W2124415162 @default.
• W2038118150 cites W2135087298 @default.
• W2038118150 cites W2147721391 @default.
• W2038118150 cites W2168456732 @default.
• W2038118150 cites W2334791345 @default.
• W2038118150 cites W2334894921 @default.
• W2038118150 cites W2337777109 @default.
• W2038118150 doi "https://doi.org/10.1046/j.1523-1755.2002.00258.x" @default.
• W2038118150 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11918739" @default.
• W2038118150 hasPublicationYear "2002" @default.
• W2038118150 type Work @default.
• W2038118150 sameAs 2038118150 @default.
• W2038118150 citedByCount "89" @default.
• W2038118150 countsByYear W20381181502012 @default.
• W2038118150 countsByYear W20381181502013 @default.
• W2038118150 countsByYear W20381181502014 @default.
• W2038118150 countsByYear W20381181502015 @default.
• W2038118150 countsByYear W20381181502016 @default.
• W2038118150 countsByYear W20381181502017 @default.
• W2038118150 countsByYear W20381181502018 @default.
• W2038118150 countsByYear W20381181502020 @default.
• W2038118150 countsByYear W20381181502021 @default.
• W2038118150 countsByYear W20381181502022 @default.
• W2038118150 countsByYear W20381181502023 @default.
• W2038118150 crossrefType "journal-article" @default.
• W2038118150 hasAuthorship W2038118150A5011328038 @default.
• W2038118150 hasAuthorship W2038118150A5042111434 @default.
• W2038118150 hasAuthorship W2038118150A5042816552 @default.
• W2038118150 hasAuthorship W2038118150A5042945151 @default.
• W2038118150 hasAuthorship W2038118150A5049273344 @default.
• W2038118150 hasAuthorship W2038118150A5055986991 @default.
• W2038118150 hasAuthorship W2038118150A5084433382 @default.
• W2038118150 hasBestOaLocation W20381181501 @default.
• W2038118150 hasConcept C126322002 @default.
• W2038118150 hasConcept C134018914 @default.
• W2038118150 hasConcept C170033053 @default.
• W2038118150 hasConcept C185592680 @default.
• W2038118150 hasConcept C202751555 @default.
• W2038118150 hasConcept C2775945674 @default.
• W2038118150 hasConcept C2776169692 @default.
• W2038118150 hasConcept C2776541429 @default.
• W2038118150 hasConcept C2776699218 @default.
• W2038118150 hasConcept C2778176769 @default.
• W2038118150 hasConcept C2778260815 @default.
• W2038118150 hasConcept C2778653478 @default.
• W2038118150 hasConcept C2778838027 @default.
• W2038118150 hasConcept C2780091579 @default.
• W2038118150 hasConcept C2780559512 @default.
• W2038118150 hasConcept C2781000923 @default.
• W2038118150 hasConcept C2781208988 @default.
• W2038118150 hasConcept C519063684 @default.
• W2038118150 hasConcept C55493867 @default.
• W2038118150 hasConcept C71924100 @default.
• W2038118150 hasConcept C81880429 @default.
• W2038118150 hasConceptScore W2038118150C126322002 @default.
• W2038118150 hasConceptScore W2038118150C134018914 @default.
• W2038118150 hasConceptScore W2038118150C170033053 @default.

• next